ZymoGenetics is the biopharmaceutical company which is mainly focused on the discovery, development and commercialization of the therapeutic proteins for averting or treating several human ailments. The company has created the wider channel of proprietary product candidates by utilizing the product discovery engine consisting of genomics, bioinformatics, protein chemistry and preclinical biology.

ZymoGenetics has developed recombinant Thrombin – rThrombin to be used as the contemporary hemostat for controlling surgical bleeding. The traditional Thrombin product which is in use since past 30 years for controlling blood loss in different surgeries has been derived from bovine blood. Bovine derived Thrombin has been accompanied by the development of antibodies which may react adversely with human blood proteins and in some typical cases such antibodies are found to be linked with serious bleeding related consequences. Hence rThrombin is developed to substitute to the traditional Thrombin to be used for controlling surgical bleeding.

The medical communities have instantly adopted these Recombinant coagulation proteins as the safer substitutes to plasma-derived proteins as established by the quick admittance of recombinant forms of coagulation factor VIII & IX.  Thrombin is a type of molecule which is naturally created by the body for helping the body to produce blood clots. Thrombin is widely used during medical surgeries when there are diffuse or discharge bleedings. The rh Thrombin is the synthetic or recombinant Thrombin. It has been noticed that the bovine Thrombin market has been consistently growing since past 5 years at an average growth rate of about 40% per annum.
ZymoGenetics is the biopharmaceutical company which is mainly focused on the discovery, development and commercialization of the therapeutic proteins for averting or treating several human ailments. The company has created the wider channel of proprietary product candidates by utilizing the product discovery engine consisting of genomics, bioinformatics, protein chemistry and preclinical biology.

ZymoGenetics has developed recombinant Thrombin – rThrombin to be used as the contemporary hemostat for controlling surgical bleeding. The traditional Thrombin product which is in use since past 30 years for controlling blood loss in different surgeries has been derived from bovine blood. Bovine derived Thrombin has been accompanied by the development of antibodies which may react adversely with human blood proteins and in some typical cases such antibodies are found to be linked with serious bleeding related consequences. Hence rThrombin is developed to substitute to the traditional Thrombin to be used for controlling surgical bleeding.

The medical communities have instantly adopted these Recombinant coagulation proteins as the safer substitutes to plasma-derived proteins as established by the quick admittance of recombinant forms of coagulation factor VIII & IX.  Thrombin is a type of molecule which is naturally created by the body for helping the body to produce blood clots. Thrombin is widely used during medical surgeries when there are diffuse or discharge bleedings. The rh Thrombin is the synthetic or recombinant Thrombin. It has been noticed that the bovine Thrombin market has been consistently growing since past 5 years at an average growth rate of about 40% per annum.